Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline as Adjunct to Citalopram in MDD
NCT05271084Phase 2Completed
- Sponsor
- Hawler Medical University
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Citalopram + Pentoxifylline with Citalopram + Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale 17 at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
pentoxifylline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05271084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05271084.